Switch theme
Sign up to access all valuation multiples
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulphate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
2014
50
LTM Revenue $42K
LTM EBITDA -$37.6M
$64.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Paradigm Biopharma has a last 12-month revenue (LTM) of $42K and a last 12-month EBITDA of -$37.6M.
In the most recent fiscal year, Paradigm Biopharma achieved revenue of $42K and an EBITDA of -$37.6M.
Paradigm Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Paradigm Biopharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $42K | XXX | $42K | XXX | XXX | XXX |
| Gross Profit | $42K | XXX | $36K | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 86% | XXX | XXX | XXX |
| EBITDA | -$37.6M | XXX | -$37.6M | XXX | XXX | XXX |
| EBITDA Margin | -89058% | XXX | -88894% | XXX | XXX | XXX |
| EBIT | -$37.6M | XXX | -$41.9M | XXX | XXX | XXX |
| EBIT Margin | -89058% | XXX | -99078% | XXX | XXX | XXX |
| Net Profit | -$37.7M | XXX | -$37.7M | XXX | XXX | XXX |
| Net Margin | -89139% | XXX | -89139% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Paradigm Biopharma's stock price is AUD 0 (or $0).
Paradigm Biopharma has current market cap of AUD 125M (or $80.1M), and EV of AUD 100M (or $64.3M).
See Paradigm Biopharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $64.3M | $80.1M | XXX | XXX | XXX | XXX | $-0.13 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Paradigm Biopharma has market cap of $80.1M and EV of $64.3M.
Paradigm Biopharma's trades at 1777.2x EV/Revenue multiple, and -1.8x EV/EBITDA.
Equity research analysts estimate Paradigm Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Paradigm Biopharma has a P/E ratio of -2.1x.
See valuation multiples for Paradigm Biopharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $80.1M | XXX | $80.1M | XXX | XXX | XXX |
| EV (current) | $64.3M | XXX | $64.3M | XXX | XXX | XXX |
| EV/Revenue | 1520.1x | XXX | 1777.2x | XXX | XXX | XXX |
| EV/EBITDA | -1.7x | XXX | -1.8x | XXX | XXX | XXX |
| EV/EBIT | -1.7x | XXX | -1.6x | XXX | XXX | XXX |
| EV/Gross Profit | 1520.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.1x | XXX | -2.3x | XXX | XXX | XXX |
| EV/FCF | -1.5x | XXX | -1.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialParadigm Biopharma's revenue per employee in the last FY averaged $1K, while opex per employee averaged $0.8M for the same period.
Paradigm Biopharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Paradigm Biopharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Paradigm Biopharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -89058% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 88653% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 99164% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Paradigm Biopharma acquired XXX companies to date.
Last acquisition by Paradigm Biopharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Paradigm Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Paradigm Biopharma founded? | Paradigm Biopharma was founded in 2014. |
| Where is Paradigm Biopharma headquartered? | Paradigm Biopharma is headquartered in Australia. |
| How many employees does Paradigm Biopharma have? | As of today, Paradigm Biopharma has 50 employees. |
| Is Paradigm Biopharma publicy listed? | Yes, Paradigm Biopharma is a public company listed on ASX. |
| What is the stock symbol of Paradigm Biopharma? | Paradigm Biopharma trades under PAR ticker. |
| When did Paradigm Biopharma go public? | Paradigm Biopharma went public in 2015. |
| Who are competitors of Paradigm Biopharma? | Similar companies to Paradigm Biopharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Paradigm Biopharma? | Paradigm Biopharma's current market cap is $80.1M |
| What is the current revenue of Paradigm Biopharma? | Paradigm Biopharma's last 12 months revenue is $42K. |
| What is the current EV/Revenue multiple of Paradigm Biopharma? | Current revenue multiple of Paradigm Biopharma is 1520.1x. |
| Is Paradigm Biopharma profitable? | Yes, Paradigm Biopharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Paradigm Biopharma? | Paradigm Biopharma's last 12 months EBITDA is -$37.6M. |
| What is Paradigm Biopharma's EBITDA margin? | Paradigm Biopharma's last 12 months EBITDA margin is -89058%. |
| What is the current EV/EBITDA multiple of Paradigm Biopharma? | Current EBITDA multiple of Paradigm Biopharma is -1.7x. |
| What is the current FCF of Paradigm Biopharma? | Paradigm Biopharma's last 12 months FCF is -$42.3M. |
| What is Paradigm Biopharma's FCF margin? | Paradigm Biopharma's last 12 months FCF margin is -100152%. |
| What is the current EV/FCF multiple of Paradigm Biopharma? | Current FCF multiple of Paradigm Biopharma is -1.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
